Aktietilbagekøb: Transaktioner i uge 27 2026

Aktietilbagekøbsprogrammet løber i perioden fra og med den 5. februar 2026 til senest den 29. januar 2027. I denne periode vil Jyske Bank erhverve egne aktier til en maksimal værdi af 3 mia. kr. i et aktietilbagekøbsprogram, jf. selskabsmeddelelse nr. 11/2026 af 5. februar 2026. Aktietilbagekøbsprogrammet gennemføres i henhold til EU‑Kommissionens forordning (EU) nr. 596/2014 … Read more

NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit

NEW YORK, July 6, 2026 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between March 31, 2025 and April 17, 2026, inclusive (the “Class Period”), of the important August 11, 2026 lead plaintiff… Source: prnewswire Country: United States

Configit figure en tant que Sample Vendor dans le Gartner® Hype Cycle™ pour le commerce numérique, 2026

Le leader mondial est reconnu parmi 11 fournisseurs cités dans le rapport 2026 COPENHAGUE, Danemark, 6 juillet 2026 /PRNewswire/ — Configit, leader mondial de la gestion du cycle de vie de la configuration (CLM), annonce aujourd’hui avoir été désigné comme Sample Vendor (fournisseur de… Source: prnewswire Country: United States

Skanska builds rock caverns for the final repository of short-lived radioactive waste in Forsmark for about SEK 1 billion

STOCKHOLM, July 6, 2026 /PRNewswire/ — Skanska has signed a contract with Svensk Kärnbränslehantering AB (SKB) for the construction of new rock caverns for the short-lived radioactive waste (SFR) final repository in Forsmark, Sweden. The contract is worth about SEK 1 billion and will be… Source: prnewswire Country: United States

Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform

LONDON, July 06, 2026 (GLOBE NEWSWIRE) — Myricx Bio, a UK-headquartered biotech company focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), today announced that it has reached agreement to be acquired by Novartis for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. … Read more